Scholarlink

Background <p>Acute‐on‐chronic liver failure (ACLF) is a syndrome characterized by systemic inflammation with a high short-term mortality rate. Syndecan-1 (SDC-1) can independently predict the 90-day mortality of patients with septic shock. However, the role of SDC-1 in ACLF remains unknown.</p> Methods <p>In this study, serum SDC-1 levels were examined in 2 cohorts, which included 174 ACLF patients. And a mouse ACLF model induced by tetrachloride, lipopolysaccharide, and D-galactosamine was established, to evaluate the effects of sulodexide and heparan sulfate (side chains of SDC-1) on ACLF in vivo.</p> Results <p>Baseline serum SDC-1 levels in 101 ACLF patients (847.72, 499.79–1511.37&#xa0;ng/ml) were significantly higher than in healthy controls (33.58, 27.08–43.34&#xa0;ng/ml) (<i>P</i> &lt; 0.0001). The baseline SDC-1 levels of patients who died or accepted a liver transplantation within 90&#xa0;days were markedly higher than those of patients who survived (<i>P</i> &lt; 0.05). A novel prognostic model (UIAS) based on upper gastrointestinal bleeding, INR, age, and SDC-1 was developed. The AUROC of the UIAS score for 28-day deterioration in ACLF patients was 0.884, indicating an obviously greater predictive performance for the outcomes of ACLF than those of the Child‐Pugh (AUROC = 0.646), MELD (AUROC = 0.713), and COSSH‐ACLF II scores (AUROC = 0.713). Moreover, we found that heparan sulfate and sulodexide could increase the expression of SDC-1 and attenuate liver injury, by promoting liver regeneration and inhibiting cell apoptosis through the activation of JAK1/STAT3 signalling.</p> Conclusions <p>Collectively, our findings suggest that SDC-1 represents a potential prognostic and therapeutic target for ACLF and should be further investigated.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Analysis of the prognostic efficacy of syndecan-1 for patients with ACLF and its functional role in liver regeneration

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月21日

查看全文
  • Yingli He,
  • Xiaoli Zhang,
  • Yichen Yao,
  • Juan Li,
  • Shan Fu,
  • Yali Feng,
  • Tianzhi Ni,
  • Ruojing Wang,
  • Qiao Zhang,
  • Yushan Liu,
  • Zhijun Liu,
  • Jinfeng Liu,
  • Yuan Yang,
  • Yingren Zhao,
  • Yalei Zhao

摘要

Background

Acute‐on‐chronic liver failure (ACLF) is a syndrome characterized by systemic inflammation with a high short-term mortality rate. Syndecan-1 (SDC-1) can independently predict the 90-day mortality of patients with septic shock. However, the role of SDC-1 in ACLF remains unknown.

Methods

In this study, serum SDC-1 levels were examined in 2 cohorts, which included 174 ACLF patients. And a mouse ACLF model induced by tetrachloride, lipopolysaccharide, and D-galactosamine was established, to evaluate the effects of sulodexide and heparan sulfate (side chains of SDC-1) on ACLF in vivo.

Results

Baseline serum SDC-1 levels in 101 ACLF patients (847.72, 499.79–1511.37 ng/ml) were significantly higher than in healthy controls (33.58, 27.08–43.34 ng/ml) (P < 0.0001). The baseline SDC-1 levels of patients who died or accepted a liver transplantation within 90 days were markedly higher than those of patients who survived (P < 0.05). A novel prognostic model (UIAS) based on upper gastrointestinal bleeding, INR, age, and SDC-1 was developed. The AUROC of the UIAS score for 28-day deterioration in ACLF patients was 0.884, indicating an obviously greater predictive performance for the outcomes of ACLF than those of the Child‐Pugh (AUROC = 0.646), MELD (AUROC = 0.713), and COSSH‐ACLF II scores (AUROC = 0.713). Moreover, we found that heparan sulfate and sulodexide could increase the expression of SDC-1 and attenuate liver injury, by promoting liver regeneration and inhibiting cell apoptosis through the activation of JAK1/STAT3 signalling.

Conclusions

Collectively, our findings suggest that SDC-1 represents a potential prognostic and therapeutic target for ACLF and should be further investigated.